Alphabet Inc Class A vs Medpace Holdings Inc — how do they compare? Alphabet Inc Class A trades at $371.56 (market cap $4.52T), while Medpace Holdings Inc trades at $534.43 (market cap $15.11B). The key difference: Alphabet Inc Class A is far larger — about 299.1× Medpace Holdings Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GOOGL | MEDP | |
|---|---|---|
Market Cap | $4.52T | $15.11B |
Sector | Media | Technology |
52-Week High | $402.62 | $620.59 |
52-Week Low | $182.97 | $308.88 |
Enterprise Value | $4.49T | $14.58B |
Dividend Yield | 0.24% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $359.51, up 1.99% on the day, with a neutral technical signal but bullish moving averages. The company demonstrates strong fundamentals with revenue growing to $402.84B in 2025 and net income surging to $132.17B, yielding a 32.8% profit margin. Recent earnings have consistently beaten expectations, and the company initiated its first dividend. Analyst sentiment remains overwhelmingly positive with an 85% buy rating and a $431.78 consensus price target, suggesting significant upside potential from current levels.
The outlook for GOOGL is positive, driven by robust earnings growth, expanding AI integration across its ecosystem, and strong cash flow generation. Key opportunities include leadership in AI infrastructure, monetization of YouTube and cloud services, and strategic investments like SpaceX. Primary risks involve regulatory scrutiny, intense competition in AI and cloud computing, and potential market volatility. The stock's current valuation, while elevated, is supported by its growth trajectory and dominant market position.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →